Describe common gene mutations and cellular signaling defects that are characteristics of RCC.
Describe prognostic and predictive factors that may be useful in determining optimal care for patients with RCC.
Describe clinical considerations in the use of metastasectomy and cytoreductive nephrectomy followed by systematic therapy for patients with mRCC.
Describe recent data regarding the safety and efficacy of novel agents targeting cell growth pathways for the treatment of RCC.
Discuss recent clinical trials investigating the safety and efficacy of targeted agents that impact the vascular and endothelial growth factor-signaling pathway for the treatment of RCC.
Who Should Attend: medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, physicial assistants and other healthcare professionals interested in the treatment and care of patients with RCC
Jun 5, 2012 - The anti-programmed death-1 monoclonal antibody BMS-936558 is active in patients with melanoma, non-small-cell lung cancer, and renal cell cancer that has progressed despite standard therapy, according to a study published online June 2 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.